2 results
Approved WMORecruiting
The main objective of this trial is to assess whether treatment adaptation based on a very early FDG-PET results in improved efficacy while minimizing treatment toxicity in advanced stage HL patients treated with BV-containing regimens, BrAVD and…
Approved WMOPending
To compare the objective response rate between patients with metastatic non-small cell lung cancer characterized by PDL-1 TPS<50% and low cTML (<300 nonsynonymous mutations) and either actionable mutation, inactivating STK11 or KEAP1…